Biolidics Ltd. is a biotechnology company specializing in the development and commercialization of innovative diagnostic solutions. Its primary function is to provide advanced diagnostic systems and kits that facilitate accurate health assessments in various medical fields. The company's product portfolio includes its flagship technology, the ClearCell® FX1 System, which enables liquid biopsy using proprietary separation technology for the isolation and enrichment of circulating tumor cells. This technology plays a significant role in the oncology sector, enhancing cancer diagnostics and treatment monitoring by offering a non-invasive method to obtain critical information from a patient's blood sample.

Biolidics Ltd. is prominent in the healthcare diagnostics market, contributing to the growing trend of personalized medicine. Its products are pivotal for medical practitioners and researchers, aiding in early disease detection and enabling targeted treatment plans. Based in Singapore, Biolidics collaborates with research institutions and healthcare providers to continually advance its diagnostic technologies and expand its reach in international markets. As such, the company's innovations are instrumental in shaping the future of diagnostic and therapeutic practices globally.